At the Speed of Liquid (Biopsy)
Improving turnaround times and detection of actionable mutations in non-small cell lung carcinoma
Olivia Gaskill | | Quick Read
The lung and thoracic oncology spotlight is increasingly shining on liquid biopsy. Genomic profiling is a pivotal tool for non-small cell lung carcinoma (NSCLC) and tissue-based analysis is the preferred method of investigation – despite being invasive and only providing a single one-place snapshot of the tumor. In recent years, the liquid biopsy has begun to challenge the standard approach, offering a minimally invasive – and spatially and temporally representative – method of investigating the tumor gene profile.
Nir Peled and colleagues explored the potential role of liquid biopsy for lung cancer patients by investigating the difference between next-generation sequencing (NGS)-based liquid biopsy and tissue-based analysis. The researchers focused on time to report and time to treat in treatment-naive NSCLC patients (1). In their pilot study, they ordered both types of biopsies for patients and found that the turnaround time for liquid biopsy results was 10 days faster than for tissue results, with actionable genes identified in 11 tissue biopsies and 14 identified by liquid biopsy.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine